Most Read Articles
Audrey Abella, 5 days ago
Use of the potent and selective PPARδ* agonist seladelpar led to improvements in histologic responses and liver chemistry in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Roshini Claire Anthony, 4 days ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

Besifovir dipivoxil maleate delivers long-term safety, efficacy in CHB

22 Aug 2020

Treatment with besifovir dipivoxil maleate (BSV) is effective and safe for long-term use in treatment-naïve and tenofovir disoproxil fumarate (TDF)-experienced patients with chronic hepatitis B (CHB), results of a phase III trial have shown.

CHB patients continued the open-label BSV study after 48 weeks of a double-blind comparison between BSV and TDF treatments. The investigators examined the antiviral efficacy and drug safety up to 144 weeks for the BSV-BSV and TDF-BSV groups.

A total of 197 patients were included in the trial, among whom 170 entered the second-year open-label phase extensional study, 158 entered the third-year open-label phase, and 153 completed the 144-week follow-up. The primary endpoint of virological response (hepatitis B virus DNA <69 IU/mL) was achieved by 87.7 percent and 92.1 percent of patients in the BSV-BSV and TDF-BSV groups, respectively, over the 144-week period (p=0.36).

No between-group difference was noted in the rates of ALT normalization and HBeAg seroconversion. There were also no drug-resistant mutations to BSV observed. Bone mineral density and renal function were well preserved in the BSV-BSV group and were significantly improved after switching therapy in the TDF-BSV group.

“BSV treatment maintained antiviral efficacy over 144-week period without any viral resistance,” the investigators said. “BSV administration was safe, well-tolerated, and effective for treatment-naïve patients with CHB as well as those who switched from TDF to BSV treatment.”

CHB remains a public health problem across the globe despite the presence of vaccines and antivirals. [J Hepatol 2017;67:370-398; Lancet 2015;386:1546-1555]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 5 days ago
Use of the potent and selective PPARδ* agonist seladelpar led to improvements in histologic responses and liver chemistry in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Roshini Claire Anthony, 4 days ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).